Home › Funds › DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. › GILD

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. position in GILD

GILEAD SCIENCES INC · Health Care

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. reported holding 80,000 shares of GILD (GILEAD SCIENCES INC) in its Q2 2026 13F filing — a position valued at US$10.1M, representing 1.13% of its reported portfolio and ranking #19 among its reported holdings. DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. has disclosed GILD holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)80.00K sh
Reported value held$10.11M
Portfolio Weight1.13%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.'s GILD position evolved

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. first disclosed a stake in GILD in Q2 2025 at 18,000 shares (US$2.0M). The position peaked in Q2 2026 at 80,000 shares, worth US$10.1M. Across 4 filings, DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 80,000 shares valued at US$10.1M — an increase of 50,000 shares quarter over quarter.. Notable position changes include a 39% increase in Q3 2025 (shares rose 10% over the following quarter), a 167% increase in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 18.00K $2.00M New
Q3 2025 25.00K $2.77M Add
Q1 2026 30.00K $4.18M New
Q2 2026 80.00K $10.11M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 35 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. held GILD?

DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. has disclosed GILD holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

What is DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.'s current position in GILD?

As of Q2 2026, DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds 80.00K shares of GILD (GILEAD SCIENCES INC), valued at $10.11M, representing 1.13% of its reported portfolio and ranking #19.

Has DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. been buying or selling GILD?

In the latest 13F filing (Q2 2026), DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. increased its position in GILD. The position peaked in Q2 2026 at 80.00K shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.